Olaparib (AZD-2281, MK-7339, Lynparza) was the first PARP inhibitor that entered clinical trials and was investigated as a targeted therapeutic agent for breast cancer involving BRCA1/2 mutation. This evidence concerns the gene BRCA1 and breast cancer.